Regenxbio Faces Class Action Over RGX-111 Misrepresentation Amid Regulatory Scrutiny

### REGENXBIO Faces Class Action Lawsuit Over RGX-111 Misrepresentations

REGENXBIO Inc. is embroiled in a class action securities lawsuit initiated by Levi & Korsinsky, LLP, targeting the gene therapy firm for alleged misrepresentations surrounding its RGX-111 program. This lawsuit spans from February 9, 2022, to January 27, 2026, claiming that REGENXBIO's executives, including its Chief Medical Officer Stephen Pakola, made excessively positive assertions regarding RGX-111's safety and efficacy for treating Mucopolysaccharidosis Type I (Hurler syndrome). The complaint contends that the firm misled investors by omitting critical adverse information that could affect the therapy's trial outcomes, particularly concerning its safety profile.

Legal documents indicate that REGENXBIO executives, during the class period, reported positive biomarker data and safety outcomes while allegedly concealing the escalating risks of serious adverse events. Signs of trouble surfaced when, on January 28, 2026, the FDA placed a clinical hold on RGX-111 after a trial participant developed an intraventricular CNS tumor. This revelation triggered a significant drop in the company’s stock price, highlighting the disconnect between the firm’s public narrative and the underlying clinical realities. Investors who suffered losses have until April 14, 2026, to seek lead plaintiff status in the ongoing litigation.

The implications of this lawsuit extend beyond just financial losses; they point to broader issues within the biotech industry regarding transparency and accountability in clinical trials. The competency of REGENXBIO's regulatory filings and public communication strategies may come under intense scrutiny. This situation raises pertinent questions about how biotech companies manage the balance between optimistic performance indicators and realistic representations of their product’s clinical profile. If substantiated, the claims in this lawsuit could influence how regulators and investors perceive corporate governance in the biotechnology sector, setting precedents for future disclosures and compliance standards.

### Regulatory Impacts and Next Steps

In parallel to the RGX-111 controversy, REGENXBIO is grappling with mixed results from its Phase 1/2 AFFINITY DUCHENNE trial for RGX-202, designed to address Duchenne muscular dystrophy (DMD). Recent interim data has not met investor expectations, further dampening confidence in the company’s developmental pipeline. These developments come at a time when the competitive landscape for DMD therapies is intensifying, raising concerns about the firm’s capacity to sustain its market position.

As the regulatory pressure mounts, REGENXBIO is at a crucial turning point. Stakeholders are closely monitoring both its upcoming clinical trial outcomes and its responses to the ongoing securities litigation. With the potential for significant ramifications on the firm’s future and its ability to navigate these challenges, REGENXBIO must enhance its regulatory strategies and communication protocols to rebuild trust and assure investors of its commitment to transparency and accountability.